title: Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
abstract: Actinic Keratoses (AKs) are epidermal skin lesions that have the potential to develop into squamous cell carcinoma. Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.
authors.affiliation: Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: J K
authors.initials: JK
authors.lastname: Rivers
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D004008:Diclofenac / Q000008:administration & dosage*; D005782:Gels; D006801:Humans; D006820:Hyaluronic Acid; D007642:Keratosis / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005782:Gels; D004008:Diclofenac; D006820:Hyaluronic Acid